Large-scale sequencing of lung adenocarcinoma has uncovered heterogeneity in mutant KRAS tumors due to concomitantly mutated tumor suppressor genes such as TP53 and LKB1, genetic subtypes that are largely mutually exclusive and which harbor distinct biologies and therapeutic susceptibilities2. The gene discussed is KRAS; the disease is lung adenocarcinoma.